Ann: Progress in Recruitment for Phase II Trial in Dogs, page-20

I'm a Trader through and through , very rarely a Day Trader,, usually a fortnight to a month , I buy in on Catalyst announcements , most rises 20% satisfies me , My target strategy is Phase II Biotech Sweet Spot, learnt a couple of years back to not be in for the final Binary decision , pass fail, Hit Primary End Point or Not..
Over the past 3 years have bought Investment Parcels in companies and generally engineer a free carry early on... PAA does have some intrinsic differences ,,the major one being a Fortune 500 Blue chip that has signed an Option should MPL do what it says on the can surrounding K9 Cancer Treatment.. Plus a Phase II V2.0 on an improved product by BRI.
Volume is a Traders allie , so as above PAA does not really appeal to many traders plus its SP isn't really that volatile ..
I was happy to pay yesterday and topped up half a million on market... should the company continue to announce progress and I see risk coming off the table happy to buy more certainty ...
You can see the wider investment community responds to news of progress....
Yesterdays Gem , Up date in December ,,,, plus the company would try for the LTH benefits to reward the SH who took part in the CR that allowed them the additional Oppies,,, so they should have strategy to bring positive news to market to ensure shareholders Value,, and enable the LTH to sell at a premium over 15c to enable them to purchase the oppies that will go straight into the company coffers ,, $2.4m is nothing to sneeze at..

Exciting times ahead ,, looking forward to the next announcement and confirmation of statements made by Robert Bishop at the Investor Evening..

The Australian and Singapore investment evenings worked a treat,,,, awareness enables a wider pool of investors to look at PAA, information enables them to make an investment decision ,, long term short term ,,, the more people that know about an opportunity the greater the possible uptake...

As Banasta said PAA are aware of shareholders pointing out the lack of wider market awareness , thats why you would have seen the Marketing in Q1 $5000, Q2 25,000 Q3 $45,000 .... Science is a discipline on its own ... and as Roger Aston said to me , Elanco are buying the Science not the Marketing .... lets hope they negotiate strongly .... and demonstrate Value or the Science..

I'm also now looking at Buying Elanco shares for their jump,, because when they announce MPL as an Elanco treatment ,,that will be done with huge budget fanfare,, Elanco have instant access to CNBC, Sky Biz UK , CNN, BBC etc etc etc

Exciting times ahead